leadf
logo-loader
viewANGLE PLC
(
AIM:AGLOTCQX:ANPCYFRA:DWV
)

ANGLE CEO reports 'progress across multiple fronts' and talks big new opportunity in immunotherapy

ANGLE PLC's (LON:AGL) (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began.

He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the US Food & Drug Administration.

Newland also discusses how he believes its ground-breaking liquid biopsy system could have a role to play helping guide trials in cancer immunotherapies.

Quick facts: ANGLE PLC

Follow
AIM:AGL

Price: 118.55 GBX

Market Cap: £278.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE lacks direction, US tech giants report thumping results as traders...

  FTSE 100 recovered from an early dip as traders digested a wave of heavyweight earnings with eyes also on the latest US Federal Reserve update this afternoon. London’s blue-chip index was up 4 at 7,000 in early dealings.  Results from the US tech giants Apple, Google and Microsoft...

on 28/7/21

2 min read